Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06003972
Other study ID # 093418-HMO-CTIL
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 4, 2021
Est. completion date March 12, 2023

Study information

Verified date August 2023
Source Hadassah Medical Organization
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Assess the anti-inflammatory effects of short-term Copaxone therapy on patients with acute decompensated heart failure. Trial Design - An open-label, randomized, prospective trial of patients hospitalized due to acute decompensation of heart failure with reduced ejection fraction. - Patients will be enrolled within 24 hours from hospital admission. - Randomization and intervention will begin within 24 hours of enrollment (and at least 24 hours after admission). - Patients will be randomized in a 1:1 ratio either to receive guideline directed medical therapy (GDMT) or GDMT plus Copaxone. - Patients assigned to intervention group will receive daily SC Copaxone 20 mg for 14 days. - Patients will be assessed during 4 time points(screening/randomization, visit 3 day, visit 14 day, visit 30 day) as elaborated in article "monitoring". - Changes in inflammatory cytokines will be compared between control and intervention group throughout 3 time points. - The trial will be approved by the institutional view board and conducted in accordance with the principles or Good Clinical Practice guidelines and the Declaration of Helsinki.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date March 12, 2023
Est. primary completion date March 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - STAGE CHF BASELINE NYHA functional class II-III and established diagnosis of ischemic cardiomyopathy - Hospitalization due to acute decompensated CHF - GDMT for at least 3 months prior to enrollment Exclusion Criteria: - Current hospitalization: - Hemodynamic instability necessitating inotropic or mechanical circulatory support - Respiratory failure necessitating invasive mechanical ventilation - Active infection - A different etiology to explain SIRS other than CHF exacerbation. Prior hospitalizations or need of intravenous diuretic therapy in the last 30 days before current hospitalization Cardiac co-morbidities: Specific HF etiologies: - Pericardial disease - Infiltrative myocardial disease - Moderate and above Valvular heart disease Acute coronary syndrome in the preceding 60 days to randomization Evidence of significant cardiac ischemia within 1 year of randomization without revascularization since Stroke or TIA in the preceding 30 days from randomization Complex congenital cardiac defect New initiation of cardiac resynchronization therapy within 60 days prior to randomization Life threatening arrhythmias /ICD ACTIVATION- in last 90 days Listing for heart transplantation or anticipated/implanted ventricular assist device Non-cardiac co-morbidities: - Glomerular filtration rate <30 mL/min/1.73m2 calculated by MDRD formula - Hepatic insufficiency classified as Child-Pugh B or C - SBP >180 mm Hg or <110 mm Hg NOT RESPONSIVE TO THERAPY - Morbid obesity with a BMI >40 kg/m2 - Severe pulmonary disease with requirement of home oxygen therapy or important nocturnal desaturation - Active treatment for malignancy in the past 2 years or neoplastic spread beyond organ of origin (lymphatic metastases included) - Hemoglobin <8 g/dL - Known previous systemic inflammatory disease - Alcohol or drug abuse Chronic treatment with Copaxone, cytotoxic, immunosuppressant or biological treatment in the past two years. Known Pregnancy Incapability of signing IC due to cognitive or mental reason Poor compliance to medical therapy or inability to complete the study Age >80 years

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Copaxone
Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
guideline directed medical therapy (GDMT)
GDMT for heart failure according to the AHA guidelines.

Locations

Country Name City State
Israel Hadassah Ein Kerem medical center-hospital ,Cardiology Department Jerusalem

Sponsors (2)

Lead Sponsor Collaborator
Hadassah Medical Organization Weizmann Institute of Science

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Endpoint %change in inflammatory cytokines from baseline to Day 3 and 2 weeks (up to 3 weeks), compared between intervention vs. control groups 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy